Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Income Taxes

Note 12—Income Taxes

Provision for income taxes

There is no provision for income taxes because the Company has incurred operating losses and capitalized certain items for income tax purposes since its inception and maintains a full valuation allowance against its net deferred tax assets. The reported amount of income tax expense for the period differs from the amount that would result from applying the federal statutory tax rate to net loss before taxes primarily because of the change in valuation allowance.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The OBBBA includes significant changes, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to certain aspects of the international tax framework and the restoration of favorable tax treatment for certain business expense provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA did not have a material impact on the Company’s consolidated financial statements. The Company generated a deferred tax asset for capitalized R&E expenditures for the years ended December 31, 2025 and 2024 which are fully offset by valuation allowances for each period.

The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows (in thousands):

	For the Year Ended December 31,
	2025						2024
	Amount			Percent			Amount			Percent
US Federal Statutory Tax Rate	$	(22,886	)		21.0	%	$	(18,748	)		21.0	%
State and local income taxes, net of federal benefit		9			(0.01	)%		(27	)		0.03	%
Tax Credits:
Research and development tax credits		(6,681	)		6.13	%		(5,257	)		5.89	%
Change in valuation allowance		25,168			(23.09	)%		20,986			(23.50	)%
Nondeductible items:
Change in fair value of Warrant Liability and note		1,632			(1.50	)%		986			(1.10	)%
Stock-based compensation		1,405			(1.29	)%		2,031			(2.27	)%
Other		1,198			(1.09	)%		29			(0.03	)%
Worldwide changes in unrecognized tax benefits		155			(0.14	)%		—			0.0	%
Total	$	—			0.0	%	$	—			0.0	%

Deferred tax assets and valuation allowance

Deferred tax assets reflect the tax effects of NOLs, tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. At December 31, 2025 and 2024, the significant components of the Company’s net deferred tax assets and liabilities are as follows (in thousands):

	For the Year Ended December 31,
	2025			2024
Deferred tax assets:
Net operating loss carryforwards	$	69,455		$	57,034
Tax credit carryforwards		13,846			7,328
Accruals and reserves		1,942			1,209
Other		65			3,429
Intangibles		4,960			4,671
Non-qualified stock options		5,767			4,433
R&E expenditures		34,172			27,709
Lease liabilities		4,213			4,116
Impairment of long-lived assets		5,987			6,115
Total deferred tax assets		140,407			116,044
Deferred tax liabilities
Right-of-use assets		(2,063	)		(1,912	)
Other		(619	)		—
Total deferred tax liabilities		(2,682	)		(1,912	)
Valuation allowance		(137,725	)		(114,132	)
Net deferred taxes	$	—		$	—

The valuation allowance is equal to the total net deferred tax asset amounts as of December 31, 2025 and 2024. ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s recent history of operating losses, management believes that recognition of the deferred tax assets net of liabilities arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.

The valuation allowance increased by $23.6 million during the year ended December 31, 2025, and increased by $22.1 million during the year ended December 31, 2024.

As of December 31, 2025, there were gross federal NOLs of $327.1 million, gross state NOLs of $13.6 million, federal tax credit carryforward of $17.4 million, and state tax credit carryforward of $1.3 million. The net operating losses and state tax credit carryforward do not expire. As of December 31, 2024, there were gross federal NOLs of $268.3 million, gross state NOLs of $11.7 million, federal tax credit carryforward of $8.7 million, and state tax credit carryforward of $1.3 million. The federal tax credit carryforward will expire in 2040. The Company files federal, foreign and state income tax returns and, in the normal course of business, the Company is subject to examination by these taxing authorities. All periods since inception are subject to examination by these taxing authorities, where applicable. There are currently no pending income tax examinations.

Pursuant to Section 382 of the Internal Revenue Code, certain substantial changes in the Company’s ownership may result in a limitation on the amount of NOL carryforwards and tax credit carryforwards that may be used in future years. Utilization of the NOL and tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company has completed studies to assess whether an ownership change has occurred through December 31, 2023. Based on these analyses, several ownership changes were identified in 2020 and an additional ownership change occurred in 2023. As a result of the ownership shift that occurred in August 2023, the Company has determined that $217.9 million of its gross federal NOLs are subject to an annual utilization limitation of $3.1 million, which can be increased in the five year period post change date for any realized built-in gain. Additionally, there were $27.1 million of research credits that will expire due to such limitations, resulting in a write-off of the related deferred tax assets and reversal of the corresponding uncertain tax positions and valuation allowance in 2023. The Company will continue to monitor equity movement and its impact on the utilization of the NOLs and credits as the Company could experience additional ownership changes subsequent to December 31, 2023, which may result in additional limitations on the utilization of NOL carryforwards and credits.